Human Papilloma Virus prevalence and type-specific relative contribution in invasive cervical cancer specimens from Italy by Mariani, Luciano et al.
RESEARCH ARTICLE Open Access
Human Papilloma Virus prevalence and
type-specific relative contribution in invasive
cervical cancer specimens from Italy
Luciano Mariani
1*, Núria Monfulleda
2, Laia Alemany
2,3, Enrico Vizza
1, Ferdinando Marandino
4, Amina Vocaturo
4,
Maria Benevolo
4, Beatriz Quirós
2, Belén Lloveras
2,5, Jo Ellen Klaustermeier
2,3, Wim Quint
6, Silvia de Sanjosé
2,3,
F Xavier Bosch
2
Abstract
Background: Cervical cancer represents an important global public health problem. It is the 2
nd most common
cancer among women worldwide. Human Papillomavirus (HPV) infection is now well-established as a necessary
cause of invasive cervical cancer (ICC) development. Only a few studies on HPV prevalence and type-specific
distribution in ICC have been conducted in Italy.
Aim: To describe the prevalence of HPV and the HPV type-specific distribution in ICC cases identified in Rome,
Italy.
Methods: 140 paraffin embedded tissue blocks of primary ICC diagnosed between 2001 and 2006 were identified
at the Regina Elena Cancer Institute in Rome (Italy). HPV was detected through amplification of HPV DNA using
SPF-10 HPV broad-spectrum primers followed by DEIA and then genotyping by LiPA25 (version 1).
Results: 134 cases were considered suitable for HPV DNA detection after histological evaluation; and overall, 90.3%
(121/134) HPV prevalence was detected. 111 cases had a single HPV type, 4 cases had an uncharacterized type
(HPVX) and 6 cases had multiple HPV infections. The five most common single HPV types among positive cases
were: HPV16 (71/121; 58.7%), HPV18 (12/121; 9.9%), HPV31, HPV45 and HPV58 (5/121; 4.1% each). 2 (1.5%)
of the single infections and 2 (1.5%) of the multiple infections contained low risk types. Statistically significant
differences in the relative contribution of HPV18 were found when comparing squamous cell carcinomas with
adenocarcinomas.
Conclusions: HPV16 and HPV18 accounted for almost 70% of all the HPV positive ICC cases. The study provides
baseline information for further evaluation on the impact of recently introduced HPV vaccines in Italy.
Background
Cervical cancer is a serious public health problem repre-
senting the 2
nd most common cancer diagnosed among
women worldwide. Around 493,000 new cases and
274,000 deaths from this disease were estimated in 2002
[1]. In this study we analyse and present data regarding
Human Papillomavirus (HPV) in invasive cervical cancer
(ICC) specimens from Italy, a country whose population
consist of 25.94 million [2] women at risk of developing
ICC (15 y.o. or older). The age-standardized incidence
rate of cervical cancer in Italy has been estimated at 8.1
new cases per 100,000 women annually [1]. Current
estimates indicate that 3,418 women are diagnosed with
ICC every year and 1,186 die from the disease, ranking
the 10
th most frequent cancer in women, however, the
3
rd most frequent cancer in women between 15 and
44 years old [1].
HPV infection is now well-established as necessary but
not sufficient cause of ICC development [3-5]. Only a
small fraction of women with cervical HPV infection
develop ICC, suggesting that other co-factors besides
HPV are necessary to cause cancer progression [6].
More than 30 different HPV types are known to infect
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into different groups according to their oncogenic
potential in ICC: established low-risk types (HPV6, 11,
40, 42, 43, 44, 54, 61, 70, 72, 81 and 89), probable high-
risk types (HPV26, 53, 66, 68, 73 and 82) and estab-
lished high-risk types (HPV16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58 and 59) [6,9]. Data from an updated meta-
analysis conducted by the International Agency for
Research on Cancer (IARC) [10,11] confirmed HPV16
as the most common type detected in ICC specimens
worldwide, followed by HPV18, together accounting for
70% of the HPVs identified in ICC specimens. After
HPV16/18, the next 6 most common HPV types were
found to be the same in all world regions (HPV45, 31,
33, 52, 58, and 35), with only slight differences in their
relative frequency over continents but, nevertheless,
accounting for an additional 20% of cervical cancers
worldwide [10,11].
Very few studies on HPV type prevalence and type-
specific distribution in ICC have been conducted in Italy
[12-17]. Thus, the main aim of this study was not only
to present HPV prevalence but also to describe HPV
type distribution in ICC specimens from Italy. This
study is part of a larger project (Catalan Institute of
Oncology-ICO survey) that aims to describe the HPV
type-specific distribution in ICC specimens from areas
with limited information available using standardized
protocols.
Methods
Study design and materials
A cross sectional period-prevalence study on archival
paraffin embedded ICC specimens was performed. 140
consecutively selected paraffin embedded tissue blocks
with ICC from women diagnosed between 2001 and
2006 were identified and retrieved from the Regina
Elena Cancer Institute in Rome, Italy. Age at diagnosis
and year of diagnosis were collected from medical
records.
Pathology and laboratory procedures: Paraffin blocks
processing, histopathological evaluation, HPV DNA
detection and typing
Selecting the paraffin blocks and microtome sectioning
was performed in Rome, under strict conditions to
avoid potential contamination and following a protocol
previously developed at ICO. Briefly, at least four paraf-
fin sections were obtained for each block (“sandwich”
method). First and last microtome sections were stained
with Haematoxylin and Eosin (H&E) for histopathologi-
cal evaluation. The sections that were cut in-between
the two H&E slides were collected in two eppendorf
type tubes for HPV DNA testing (one tube for initial
testing and the other for back-up). A tissue-free paraffin
block was cut after each study block to avoid HPV
carry-over from block to block. A new blade was used
for each study block, and the microtome was cleaned
with Histoclear II, a xylene substitute, and 70% alcohol.
Paraffin blocks containing non HPV-related lesions,
such as, non HPV-related tumours or non-tumour biop-
sies were blindly included and analyzed as controls in
the process for further quality control of laboratory
results.
The pathology classification of the histopathological
diagnosis was done at ICO following the consensus
criteria established by an expert panel of collaborating
pathologists. These criteria were based on the World
Health Organization (WHO) classification of uterine
cervix tumours [18]. The pathology evaluation
included: diagnosis of histological type (ICC: -squa-
mous cell carcinoma, adenocarcinoma, adenosquamous
carcinoma, other types-; non-invasive cervical cancer
and control tissue specimen); presence of normal
mucosa or pre-neoplastic lesions adjacent to ICC (Cer-
vical Intraepithelial Neoplasia - CIN1, 2, or 3; Adeno-
carcinoma in Situ-AIS); degree of necrosis; tumour
infiltration expressed by % (quantity of necrosis/infil-
trating component of the tumour in the total of the
section), and adequacy of the sample to proceed to
HPV testing. A sample was determined to be adequate
for HPV analysis if invasive cancer was observed on
both H&E stained sections of the study specimen.
DNA isolation was performed by treating the cut sec-
tions of paraffin embedded tissues with 250 μl of freshly
prepared 0.1% proteinase Ks o l u t i o n( 5m MT r i sH C l ,
0.1 mM EDTA, 0.05% Tween 20). The samples were
incubated at 56°C for 18 hours to overnight. Proteinase
K was then heat inactivated at 95°C for 10 minutes.
Short Polymerase Chain Reaction Fragment - using bio-
tin labelled SPF-10 primers [19,20] was performed using
10 μl of a 1:10 dilution of the crude DNA isolate in a
final reaction volume of 50 μl. Presence of HPV DNA,
was determined by a probe hybridization technique that
contains a mixture of HPV specific probes recognizing
at least 54 mucosal HPV genotypes in a microtiter plate
format (DNA Enzyme Immuno Assay -DEIA). Briefly,
10 μl of the PCR product was incubated in a hybridiza-
tion buffer in a streptavidin-coated microtiter plates.
T h ep l a t e sw e r ew a s h e da n dt h ec a p t u r e dP C Rp r o d u c t
was denatured using NaOH. Subsequently, digoxigenin
(DIG)-labelled HPV-specific probes were added and
following incubation, the plates were washed 3 times.
Finally, an anti-DIG alkaline phosphatase substrate was
added to the wells and after a short incubation time, the
optical densities were determined. Optical densities
(OD450) were read on a microtiter plate reader (Bio-
tek) [19]. For genotyping HPV DNA, 10 μlo ft h eP C R
amplimers of the HPV DNA positive samples, as
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LiPA25 version 1. (Labo Biomedical Products, Rijswijk,
The Netherlands), that can detect 25 different high-risk
and low-risk HPV types (6, 11, 16, 18, 31, 33, 34, 35, 39,
40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70,
74). The sequence variation within the SPF-10 primers
allows the recognition of these different HPV genotypes,
except for types 68 and 73, as their interprimer regions
are identical and cannot be distinguished by this test.
Positive hybridization on the strips is visualized as a
purple band by means of a precipitating colour substrate
on the probe site. Specimens that were identified as
HPV DNA positive, but did not hybridize with any of
the 28 LiPA probes patterns, were coded as HPV type X
(uncharacterized type). SPF-10 PCR, detection and
typing were performed at ICO.
Statistical analysis
Data analysis was performed with the Statistical Package
SPSS 14.0. Overall and type-specific HPV prevalence
(within the total of samples analyzed) and type-specific
relative contribution (within the HPV positive cases)
were analyzed and 95% confidence intervals (95% CIs)
for proportions were calculated. To estimate the HPV
type distribution, single and multiple HPV infections
were considered either separately or combined. Stratified
analyses of overall HPV and type-specific distributions
by age at diagnosis and histological characteristics were
performed. Age was recoded as a categorical variable
(≤39, 40-49, 50-59, and ≥60 years). Statistical signifi-
cance for two sided chi-squared and linear trend tests
were set at 0.05 levels [21].
Ethical issues
Specimens were received at the reference laboratory in
Barcelona (ICO) under an anonymous manner (without
name and/or original medical record number nor histo-
logy report). All protocols were approved by local and
ICO ethical committees. The study’s progress was over-
seen by an international steering committee specifically
created for the supervision and to act as an advisory
committee for handing critical ethics as well as scientific
issues of the project.
Results
After histological evaluation, 134 ICC specimens from
the original 140 cases were considered suitable for HPV
testing; 6 specimens were excluded because they were
classified as non-invasive cervical cancers. Mean age of
HPV analyzed cases was 52.4 years (Standard Deviation:
14.2; minimum 23 years, maximum value 85 years).
Squamous cell carcinoma was the most frequent histo-
logical type (83.6%), followed by adenocarcinoma (12.7%)
and adenosquamous cell carcinoma (0.8%). Other
histopathological types accounted for 3.0%, and were
classified as 2 undifferentiated carcinomas, 1 poorly dif-
ferentiated large cell carcinoma and 1 basal adenoid car-
cinoma. Microscope slides were systematically reviewed
by the pathologists to identify characteristics that could
affect detection such as grade of necrosis, tumour infil-
tration, concomitant lesions or if mucosa was associated.
Table 1 describes the different parameters that were eval-
uated without considering HPV status. The majority of
specimens (89.6%) had a low percentage of necrotic cells
(grade of necrosis was below 25%). Tumour infiltration
under 25% was rarely seen (6.0%). 81.3% of cases had no
pre-invasive lesion associated: CIN I was identified in
only one HPV positive case, CIN III was observed in 22
cases (16.4%) and AIS lesions were found in 4 cases
(3.0%), two of which were concomitant with a CIN III
lesion. Almost two thirds of the series had no associated
mucosa (66.4%). There were no major differences in
HPV positivity by age at diagnosis and histological fea-
tures evaluated, as shown in Table 1.
Data on HPV testing and typing is summarized in
Table 2. 121 of 134 specimens were HPV DNA positive
(90.3%; 95% CI: 84.0%-94.7%). Among the HPV positive
cases, 111 were identified as single HPV types (91.7%), 4
were HPVX (3.3%) and 6 harboured multiple HPV types
(5.0%). The five most common single types among posi-
tive cases were: 71 HPV16 (58.7%), 12 HPV18 (9.9%) and
5 of each HPV31, HPV45 and HPV 58 (4.1%). Multiple
infection combinations were: HPV16&18, HPV45&51,
HPV31&42, HPV31&52, HPV6&53&66 and HPV53&
56&58. In two cases, exclusively low risk types were
identified, one HPV42 and one HPV70 as single infec-
tions. These were repeated at least twice, and in both
occasions showed strong hybridization patterns at the
probe sites. HPV6 and HPV42 also were harboured in
two multiple infections (HPV6&53&66, HPV31&42).
HPV16 relative contribution was higher in squamous
cell carcinoma (62.4%) than in adenocarcinoma (43.8%)
with HPV16 as the most frequent type identified in both
(p > 0.05). HPV18 was more prevalent in adenocarcino-
mas (31.3%) than in squamous cell carcinomas (5.0%)
(p < 0.05). HPV31, HPV45 and HPV58 single infections
were as frequent as HPV18 in squamous cell carcinoma
(5.0%) (Figure 1).
The relative contribution of HPV16 was inversely
related to increasing age. Nearly 72% HPV16 single
types were identified within the youngest age group
(<40 years), 57% in the 40-49 years group and 54% in
women older than 49 years; although these differences
were not statistically significant, p-trend test >0.05.
Discussion
In the present study a high proportion (90.3%) of the
ICC specimens analyzed was HPV DNA positive.
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HPV positive cases. Types HPV31, HPV45, HPV58 and
HPV33 also were identified with no major distinction
b e t w e e nt h e mi nt e r m so fr e l a tive importance. Collec-
tively, these types accounted for an additional 15.6% of
single infections.
Several meta-analyses on HPV detection among ICC
have been published by IARC [10,11] presenting an
overall HPV prevalence by geographical area ranging
from 79.3% in Asia to 88.1% in North America. In pub-
lished data updated in 2007 [11], the HPV positivity
increased to 87% (ranging from 86% to 94% by region).
These variations or the increase of the HPV positivity
could be explained by the differences on the metho-
dologies used to determine HPV DNA positivity,
histopathologic quality of the samples and the type of
specimens analyzed (biopsies, surgical specimens, fresh/
frozen tissue samples). The overall HPV positivity in
our study was even slightly higher given that a highly
sensitive PCR technology was used [19] along with a
prior examination of the tissue sections by pathologists
to ensure the quality of the specimens before continuing
onto testing.
3,607 women with incident and histological confirmed
cervical cancer recruited in 25 countries were used for a
pooled analysis of data in an international survey of cervi-
cal cancer HPV types and a multicenter case-control
study, both co-coordinated by the IARC [22]. The study
published the two most common HPV types as follows:
57.4% prevalence for HPV16 (from 52% in Asia to 58%
Table 1 Detection of HPV DNA in ICC specimens from Italy, by age at diagnosis and histopathological information
HPV analyzed cases (n) HPV positive cases (n) HPV prevalence % (95% CI)
Age (years)
≤39 29 25 86.2 (68.7-96.1)
40-49 36 35 97.2 (85.5-99.9)
50-59 27 25 92.6 (75.7-99.1)
≥60 42 36 85.7 (71.5-94.6)
Histological type
Squamous cell carcinoma 112 101 90.2 (83.1-95.0)
Adenocarcinoma 17 16 94.1 (71.3-99.8)
Adenosquamous cell carcinoma 1 1 100.0 (25.0-100.0)
Other 4 3 75.0 (19.4-99.4)
Degree of Necrosis
<25% 120 110 91.7 (85.2-95.9)
25%-50% 12 11 91.7 (61.5-99.8)
51%-75% 2 0 0.0 (0.0-84.2)
Tumour Infiltration
<10% 1 1 100.0 (25.0-100.0)
10%-25% 7 6 85.7 (42.1-99.6)
26%-50% 43 38 88.4 (74.9-96.1)
51%-75% 41 39 95.1 (83.5-99.4)
>75% 42 37 88.1 (74.4-96.0)
Mucosa
Squamous mucosa 15 14 93.3 (68.0-99.8)
Endocervical mucosa 10 9 90.0 (55.5-99.7)
Squamous and endocervical mucosa 20 18 90.0 (68.3-98.8)
No mucosa 89 80 89.9 (81.7-95.3)
CIN III (*)
Yes 22 20 90.9 (70.8-98.9)
No 112 101 90.2 (83.1-95.0)
AIS (**)
Yes 4 4 100.0 (39.8-100)
No 130 117 90.0 (83.5-94.6)
Total 134 121 90.3 (84.0-94.7)
(*) CIN III: Cervical Intraepithelial Neoplasia III - Adjacent to ICC.
(**) AIS: Adenocarcinoma in Situ - Adjacent to ICC.
95% CI: 95% Confidence Interval.
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13% in South and Central America to 22% in North
America). In our study HPV16 also was the most com-
mon type in ICC, with a prevalence of around 53%, in
agreement with previous reports. Although HPV18 was
the second most frequent type, its prevalence of approxi-
mately 9.0% in Italy was considerably lower compared
with previous reports but still in agreement with previous
studies conducted in Italy (Table 3) [12-17]. Our data
were in agreement regarding HPV16 prevalence with
other studies conducted in Italy. Although based on
small numbers, in our study we observed HPV58 to be as
prevalent as HPV45, which was consistent with previous
observations [10,11]. Moreover, when compared with
data from the WHO/ICO HPV information centre for
ICC (Table 4), in neighbouring regions and countries,
HPV16 and 18 almost were first and second HPV types
in frequency position, followed by HPV31, 33, 45, 51 and
52 with slightly prevalence variation [23].
The association between HPV type and histological
type has been described in a large number of studies
[10,11]. Tenti et al. reported a slightly higher prevalence
of HPV18 (29.7%) than HPV16 (28.3%) in a study con-
ducted in Italy on 138 adenocarcinomas of the cervix
[12]. Similarly, in the present study HPV16 was shown to
be more common in squamous cell carcinomas whereas
HPV18 was more common in adenocarcinomas.
Even though a high-sensitive HPV DNA PCR based
technology was used for detection and HPV typing
(SPF-10-LiPA25), our study is not without some limita-
tions. Sample collection was available from only one
hospital in Italy (the Regina Elena National Cancer Insti-
tute of Rome). Although the number of samples ana-
lyzed is limited and obviously not representative of the
whole country, they were orig i n a t e df r o mas y s t e m a t i c
collection at a national cancer reference centre provid-
ing a potential good representation of all cases in the
country.
Table 2 Distribution of HPV types in ICC specimens from Italy
HPV type-specific positive cases
(n)
HPV prevalence (95% CI)
(*)
Relative HPV type contribution (95% CI)
(**)
Single types 111 82.2 (75.4-88.8) 91.7 (85.3-96.0)
HPV16 71 53.0 (44.2-61.7) 58.7 (49.4-67.5)
HPV18 12 9.0 (4.7-15.1) 9.9 (5.2-16.7)
HPV31 5 3.7 (1.2-8.5) 4.1 (1.4-9.4)
HPV45 5 3.7 (1.2-8.5) 4.1 (1.4-9.4)
HPV58 5 3.7 (1.2-8.5) 4.1 (1.4-9.4)
HPV33 4 3.0 (0.8-7.5) 3.3 (0.9-8.2)
HPV35 2 1.5 (0.2-5.3) 1.7 (0.2-5.8)
HPV51 2 1.5 (0.2-5.3) 1.7 (0.2-5.8)
HPV52 2 1.5 (0.2-5.3) 1.7 (0.2-5.8)
HPV42 1 0.7 (0.0-4.1) 0.8 (0.0-4.5)
HPV56 1 0.7 (0.0-4.1) 0.8 (0.0-4.5)
HPV70 1 0.7 (0.0-4.1) 0.8 (0.0-4.5)
Multiple types 6 4.5 (1.7-9.5) 5.0 (1.8-10.5)
HPV 16&18 1 0.7 (0.0-4.1) 0.8 (0.0-4.5)
HPV 45&51 1 0.7 (0.0-4.1) 0.8 (0.0-4.5)
HPV 31&42 1 0.7 (0.0-4.1) 0.8 (0.0-4.5)
HPV 31&52 1 0.7 (0.0-4.1) 0.8 (0.0-4.5)
HPV 6&53&66 1 0.7 (0.0-4.1) 0.8 (0.0-4.5)
HPV 53&56&58 1 0.7 (0.0-4.1) 0.8 (0.0-4.5)
HPVX (Unknown type) 4 3.0 (0.1-5.9) 3.3 (0.9-8.2)
Potential vaccine
impact (***)
HPV16, 18, 16&18 84 62.7 (53.9-70.9) 69.4 (60.4-77.5)
Total HPV positive cases 121 90.3 (84.0-94.7) 100.0
Total HPV analyzed cases 134
(*) HPV prevalence (95% CI), among HPV analyzed cases (n = 134).
(**) HPV type-specific relative contribution (95% CI), among HPV positive cases (n = 121).
(***) Considering a 100% vaccine efficacy (without cross-protection).
95% CI: 95% Confidence Interval.
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Figure 1 HPV type distribution among ICC HPV positive cases, regarding histology.
Table 3 Comparison of HPV prevalence in ICC specimens among studies conducted in Italy
Author Year Tecnique used Samples
analized
HPV +
cases
(%)
HPV16 HPV18 HPV31 HPV33 HPV45 HPV58 HPVx Other M.I.
Gioele G.
Garzetti
et al. [13]
1998 PCR primers for HPV6,
11, 16, 18, 31, 33, 34,
35, 42, 51, 56 & 58
32 22
(68.8%)
16
(50.0%)
4
(12.5%)
2
(6.3%)
0
(0.0%)
- 0
(0.0%)
1
(3.1%)
0
(0.0%)
1
(3.1%)
Ciotti et al.
[14]
2005 MY09/11, GP5+/6+ 102 92
(90.2%)
59
(57.8%)
8
(7.8%)
6
(5.9%)
10
(9.8%)
3
(2.9%)
4
(3.9%)
0
(0.0%)
14
(13.7%)
12
(11.8%)
Del mistro
et al. [15]
2006 GP5+/6+ 48 44
(91.7%)
32
(66.7%)
4
(8.3%)
1
(2.1%)
4
(8.3%)
2
(4.2%)
2
(4.2%)
0
(0.0%)
4
(8.3%)
5
(10.4%)
Tornesello
et al. [16]
2006 MY09/11 & GP5+/6+ 65 53
(81.5%)
39
(60.0%)
4
(6.2%)
3
(4.6%)
4
(6.2%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
4
(6.2%)
1
(1.5%)
Gargiulo
et al. [17]
2007 Linear array 31 29
(93.5%)
19
(61.3%)
4
(12.9%)
3
(9.7%)
4
(12.9%)
4
(12.9%)
1
(3.2%)
0
(0.0%)
28
(90.3%)
14
(45.2%)
Present
study
2008 SPF10/DEIA/LIPA25 134 121
(90.3%)
72
(53.7%)
13
(9.7%)
7
(5.2%)
4
(3.0%)
6
(4.5%)
6
(4.5%)
4
(3.0%)
17
(12.7%)
6
(4.5%)
AVERAGE 412 361
(87.6%)
237
(57.5%)
37
(9.0%)
22
(5.3%)
26
(6.3%)
15
(3.6%)
13
(3.2%)
5
(1.2%)
67
(16.3%)
39
(9.5%)
M.I.: Multiple infections. A multiple infection is counted once on every type involved. In example: HPV16&74 is counted as n = 1 in HPV16 and n = 1 in HPV74.
The sum of the total % may exceed 100%.
Gioele G. Garzetti et al.: Histology: 32 patients with FIGO Stage I and IIA SCC who had undergone primary radical hysterectomy and bilateral oophorectomy.
Patients with no SCC histotype were excluded. M.I.: HPV16&31.
Ciotti et al.: Histology: 102 SCC. M.I.: n = 4 HPV31&54; n = 3 HPV16&33; n = 3 HPV16&18; n = 1 HPV33&54; n = 1 HPV16&53. Other: n = 8 single infections
(n = 3 HPV56; n = 2 HPV52, n = 1 HPV51, n = 1 HPV35, n = 1 HPV73) and n = 6 in M.I. (n = 4 HPV31&54, n = 1 HPV33&54, n = 1 HPV16&53).
Del Mistro et al.: Histology: 48 SCC (43 SCC and 5 Adenocarcinomas). M.I.: n = 5 (n = 3 HPV16&18; n = 1 HPV16&31; n = 1 HPV56&70). Other: n = 2 in single
infections (n = 1 HPV35; n = 1 HPV52) and n = 2 in M.I: (n = 1 HPV56; n = 1 HPV70).
Tornesello et al.: 65 SCC. M.I.: n = 1 HPV16&73. Other: n = 3 single infections (n = 1 HPV35, n = 1 HPV62, n = 1 HPV82) and n = 1 M.I (HPV16&73).
Gargiulo et al.: Histology: 31 cervical cancer samples analyzed with non histological sub classification specified. M.I.: n = 14, already counted in Table 2 of the
article. They do not specify all the M.I as some were up to more the 5 HPV types. Only the most prevalent ones are described. Other: n = 5 HPV52; n = 4 HPV61;
n = 3 HPV70; n = 3 HPV84; n = 2 HPV51; n = 2 HPV62; n = 1 HPV35; n = 1 HPV39; n = 1 HPV56; n = 1 HPV53; n = 1 HPV55; n = 1 HPV66; n = 1 HPV67; n = 1
HPV81; n = 1 HPV89.
Present study: Histology: 134 samples (122 SCC, 17 Adenocarcinomas, 1 adenosquamous and 4 other histological types). M.I.: n = 6 (n = 1 HPV16&18; n = 1
HPV45&51; n = 1 HPV31&42; n = 1 HPV31&52; n = 1 HPV6&53&66; n = 1 HPV53&56&58). Other: n = 9 in single infections (n = 2 HPV35; n = 2 HPV51; n = 2
HPV52; n = 1 HPV42; n = 1 HPV56; n = 1 HPV70) and n = 8 in M.I (n = 2 HPV53; n = 1 HPV51; n = 1 HPV52; n = 1 HPV42; n = 1 HPV6; n = 1 HPV66; n = 1
HPV56).
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Our data is in good agreement with previously pub-
lished information and indicate that a HPV vaccine tar-
geting HPV types 16 and 18 could potentially prevent
70% of HPV positive cervical cancers. The earlier age at
diagnosis of most HPV 16 related cancers may have
implications in future strategies of prevention in adult
women.
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